Stockreport

Royalty Pharma Reports Third Quarter 2025 Results [Yahoo! Finance]

Royalty Pharma plc - Class A Ordinary Shares  (RPRX) 
US:NASDAQ Investor Relations: ir.reprosrx.com/investor-relations
PDF Net cash provided by operating activities of $703 million Raised full year 2025 guidance: Portfolio Receipts expected to be $3,200 to $3,250 million NEW YORK, Nov. [Read more]